Breast cancer—epidemiology, classification, pathogenesis and treatment (review of literature)

B Smolarz, AZ Nowak, H Romanowicz - Cancers, 2022 - mdpi.com
Simple Summary Breast cancer is the most-commonly diagnosed malignant tumor in women
in the world, as well as the first cause of death from malignant tumors. The incidence of …

Advances in the prevention and treatment of obesity-driven effects in breast cancers

K Chen, J Zhang, NM Beeraka, C Tang… - Frontiers in …, 2022 - frontiersin.org
Obesity and associated chronic inflammation were shown to facilitate breast cancer (BC)
growth and metastasis. Leptin, adiponectin, estrogen, and several pro-inflammatory …

[PDF][PDF] Breast Cancer: Updated and Deep Insights

KM Cuthrell, N Tzenios - International Research Journal of …, 2023 - researchgate.net
Breast cancer is the most common cancer diagnosed in females throughout the entire world,
and it is also the primary reason why people lose their lives due to malignant tumors. The …

Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides

D Huang, X Zhu, S Ye, J Zhang, J Liao, N Zhang… - Nature, 2024 - nature.com
Emerging data have shown that previously defined noncoding genomes might encode
peptides that bind human leukocyte antigen (HLA) as cryptic antigens to stimulate adaptive …

Triple-negative breast cancer: treatment challenges and solutions

J Collignon, L Lousberg, H Schroeder… - Breast Cancer: Targets …, 2016 - Taylor & Francis
Triple-negative breast cancers (TNBCs) are defined by the absence of estrogen and
progesterone receptors and the absence of HER2 overexpression. These cancers represent …

Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trial

V Galimberti, BF Cole, S Zurrida, G Viale, A Luini… - The lancet …, 2013 - thelancet.com
Background For patients with breast cancer and metastases in the sentinel nodes, axillary
dissection has been standard treatment. However, for patients with limited sentinel-node …

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by …

M Piccart, LJ van't Veer, C Poncet… - The Lancet …, 2021 - thelancet.com
Background The MINDACT trial showed excellent 5-year distant metastasis-free survival of
94· 7%(95% CI 92· 5–96· 2) in patients with breast cancer of high clinical and low genomic …

[HTML][HTML] Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early …

A Goldhirsch, WC Wood, AS Coates, RD Gelber… - Annals of oncology, 2011 - Elsevier
Abstract The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel
adopted a new approach to the classification of patients for therapeutic purposes based on …

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Early Breast Cancer Trialists' Collaborative Group - The lancet, 2011 - thelancet.com
Background As trials of 5 years of tamoxifen in early breast cancer mature, the relevance of
hormone receptor measurements (and other patient characteristics) to long-term outcome …

Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial

AE Giuliano, KK Hunt, KV Ballman, PD Beitsch… - Jama, 2011 - jamanetwork.com
Context Sentinel lymph node dissection (SLND) accurately identifies nodal metastasis of
early breast cancer, but it is not clear whether further nodal dissection affects survival …